| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
254,036,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$22.93 - $22.93 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bruno Anthony D |
Exec. V.P., Corp. Development |
• – – |
2011-01-31 |
4 |
AS |
$23.35 |
$50,248 |
D/D |
(2,152) |
684,601 |
|
- |
|
| Boissonneault Roger M |
CEO & President |
• • – |
2011-01-31 |
4 |
AS |
$23.35 |
$192,120 |
D/D |
(8,228) |
2,000,062 |
|
- |
|
| Reichel W Carl |
President, Pharmaceuticals |
• – – |
2011-01-31 |
4 |
AS |
$23.35 |
$50,248 |
D/D |
(2,152) |
749,244 |
|
- |
|
| Gilligan Claire A |
Senior V.P. Global Quality |
• – – |
2011-01-21 |
4 |
S |
$23.62 |
$21,945 |
D/D |
(929) |
55,837 |
|
- |
|
| Fuhrmann Rochelle |
Senior V.P., Global Finance |
• – – |
2011-01-21 |
4 |
S |
$23.62 |
$11,457 |
D/D |
(485) |
11,788 |
|
- |
|
| Ellman Herman |
Senior V.P., Clinical Devel. |
• – – |
2011-01-21 |
4 |
S |
$23.62 |
$27,496 |
D/D |
(1,164) |
227,725 |
|
- |
|
| Cross Leland H |
Senior V.P., Tech. Operations |
• – – |
2011-01-21 |
4 |
S |
$23.62 |
$24,898 |
D/D |
(1,054) |
342,061 |
|
- |
|
| Howard Alvin D |
Sr. V.P., Regulatory Affairs |
• – – |
2011-01-21 |
4 |
S |
$23.62 |
$28,795 |
D/D |
(1,219) |
205,690 |
|
- |
|
| Bruno Anthony D |
Exec. V.P., Corp. Development |
• – – |
2011-01-21 |
4 |
AS |
$23.62 |
$96,780 |
D/D |
(4,097) |
686,753 |
|
- |
|
| Reichel W Carl |
President, Pharmaceuticals |
• – – |
2011-01-21 |
4 |
AS |
$23.62 |
$96,757 |
D/D |
(4,096) |
751,396 |
|
- |
|
| Boissonneault Roger M |
CEO & President |
• • – |
2011-01-21 |
4 |
AS |
$23.62 |
$320,789 |
D/D |
(13,580) |
2,008,290 |
|
- |
|
| Herendeen Paul |
Exec. V.P. and CFO |
• – – |
2011-01-21 |
4 |
S |
$23.62 |
$96,757 |
D/D |
(4,096) |
748,900 |
|
- |
|
| Fuhrmann Rochelle |
Senior V.P., Global FinanceOff |
• – – |
2011-01-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,273 |
|
- |
|
| Howard Alvin D |
Sr. V.P., Regulatory Affairs |
• – – |
2011-01-11 |
4 |
S |
$23.85 |
$27,022 |
D/D |
(1,133) |
206,909 |
|
- |
|
| Gilligan Claire A |
Senior V.P. Global Quality |
• – – |
2011-01-11 |
4 |
S |
$23.85 |
$19,772 |
D/D |
(829) |
56,766 |
|
- |
|
| Ellman Herman |
Senior V.P., Clinical Devel. |
• – – |
2011-01-11 |
4 |
S |
$23.85 |
$24,566 |
D/D |
(1,030) |
228,889 |
|
- |
|
| Cross Leland H |
Senior V.P., Tech. Operations |
• – – |
2011-01-11 |
4 |
S |
$23.85 |
$24,566 |
D/D |
(1,030) |
343,115 |
|
- |
|
| Herendeen Paul |
Exec. V.P. and CFO |
• – – |
2010-11-24 |
4 |
GD |
$0.00 |
$0 |
D/D |
12,000 |
752,996 |
|
- |
|
| Fawzi Mahdi B |
President, Research & Develop. |
• – – |
2010-10-21 |
4 |
S |
$24.20 |
$59,701 |
D/D |
(2,467) |
23,833 |
|
- |
|
| Credit Suisse First Boston |
10% Owner |
– – • |
2010-09-30 |
4 |
S |
$21.48 |
$322,200,000 |
I/I |
(15,000,000) |
10,225,584 |
|
- |
|
| Gilligan Claire A |
Senior V.P. Global Quality |
• – – |
2010-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
2,040 |
57,595 |
|
- |
|
| Credit Suisse First Boston |
10% Owner |
– – • |
2010-09-29 |
4 |
S |
$22.50 |
$7,263,191 |
I/I |
(322,797) |
25,225,584 |
|
- |
|
| Credit Suisse First Boston |
10% Owner |
– – • |
2010-09-28 |
4 |
S |
$22.53 |
$12,955,440 |
I/I |
(575,000) |
25,548,651 |
|
- |
|
| Alpinvest Partners Later Stage Co-Investments Cust |
*See Remarks |
– – • |
2010-09-27 |
4 |
S |
$22.68 |
$14,765,315 |
D/D |
(651,028) |
0 |
|
- |
|
| Alpinvest Partners Later Stage Co-Investments Cust |
*See Remarks |
– – • |
2010-09-24 |
4 |
S |
$22.78 |
$37,578,913 |
D/D |
(1,649,645) |
651,028 |
|
- |
|
380 Records found
|
|
Page 10 of 16 |
|
|
